CD8 + T cell targeting of tumor antigens presented by HLA-E
Science Advances · 2024
DOI: 10.1126/sciadv.adm7515 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Ravi F Iyer und 23 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA. Hauptthemen laut MEDLINE: Antigens, Neoplasm, CD8-Positive T-Lymphocytes, HLA-E Antigens. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
The nonpolymorphic major histocompatibility complex E (MHC-E) molecule is up-regulated on many cancer cells, thus contributing to immune evasion by engaging inhibitory NKG2A/CD94 receptors on NK cells and tumor-infiltrating T cells. To investigate whether MHC-E expression by cancer cells can be targeted for MHC-E–restricted T cell control, we immunized rhesus macaques (RM) with rhesus cytomegalovirus (RhCMV) vectors genetically programmed to elicit MHC-E–restricted CD8 + T cells and to express established tumor-associated antigens (TAAs) including prostatic acidic phosphatase (PAP), Wilms tumor-1 protein, or Mesothelin. T cell responses to all three tumor antigens were comparable to viral antigen-specific responses with respect to frequency, duration, phenotype, epitope density, and MHC restriction. Thus, CMV-vectored cancer vaccines can bypass central tolerance by eliciting T cells to noncanonical epitopes. We further demonstrate that PAP-specific, MHC-E–restricted CD8 + T cells from RhCMV/PAP-immunized RM respond to PAP-expressing HLA-E + prostate cancer cells, suggesting that the HLA-E/NKG2A immune checkpoint can be exploited for CD8 + T cell–based immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.
- Department of Urology and Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai, New York, NY 10029, USA.
- Vir Biotechnology, San Francisco, CA 14158, USA.
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
ORCID-Profile: Ravi F Iyer, Marieke C Verweij, Sujit S Nair, David Morrow, Mandana Mansouri, Dimple Chakravarty, Teresa Beechwood, Christine Meyer, Andrea Selseth, Nessy John, Tin Htwe Thin, Colin Havenar-Daughton, Michael K Axthelm, Alan Korman, Nina Bhardwaj, Ashutosh K Tewari, Scott Hansen, Daniel Malouli, Louis J Picker, Klaus Früh
Förderung
- NIAID NIH HHS
- NIH HHS
Zitieren
APA
Iyer, R. F., Verweij, M. C., Nair, S. S., Morrow, D., Mansouri, M., Chakravarty, D., Beechwood, T., Meyer, C., Uebelhoer, L., Lauron, E. J., Selseth, A., John, N., Thin, T. H., Dzedzik, S., Havenar-Daughton, C., Axthelm, M. K., Douglas, J., Korman, A., Bhardwaj, N., …, & Früh, K. (2024). CD8 + T cell targeting of tumor antigens presented by HLA-E. Science Advances. https://doi.org/10.1126/sciadv.adm7515
Vancouver
Iyer RF, Verweij MC, Nair SS, Morrow D, Mansouri M, Chakravarty D, et al. CD8 + T cell targeting of tumor antigens presented by HLA-E. Science Advances. 2024. doi:10.1126/sciadv.adm7515
BibTeX
@article{Iyer2024,
author = {Iyer, Ravi F and Verweij, Marieke C and Nair, Sujit S and Morrow, David and Mansouri, Mandana and Chakravarty, Dimple and Beechwood, Teresa and Meyer, Christine and Uebelhoer, Luke and Lauron, Elvin J and Selseth, Andrea and John, Nessy and Thin, Tin Htwe and Dzedzik, Siarhei and Havenar-Daughton, Colin and Axthelm, Michael K and Douglas, Janet and Korman, Alan and Bhardwaj, Nina and Tewari, Ashutosh K and Hansen, Scott and Malouli, Daniel and Picker, Louis J and Früh, Klaus},
title = {CD8 + T cell targeting of tumor antigens presented by HLA-E},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.adm7515}
}
EUVIMED